Hangzhou-based biotech firm Ascletis has received US$20 million from Goldman Sachs, bringing the company's total fundraising to US$55 million, according to a company announcement. Ascletis received its first round of US$35 million investment led by C-Bridge Capital, Tasly Pharmaceutical and Pavilion Capital three months ago in September. The company says it will use the latest […]

Visit ChinaMoneyNetwork.com for more daily finance news, including audio and video Internet podcasts covering important investment news and financial events in China. Follow us on Twitter @chinamoneypod subscribe to all episodes on iTunes.